Mavatar Recognized as One of Sweden’s Most Exciting AI Health Companies

Fantastic news! In Breakit’s latest overview of Swedish AI companies, Mavatar has been recognized as one of the most exciting players in the healthtech space.
Read the full article here (in Swedish): Breakit Article (subscription required)

Here's a brief summary of what sets Mavatar apart

Mavatar’s data-driven AI platform for precision health spans two key business areas. Today, it is used by biotech-focused pharmaceutical companies and medical institutions to accelerate and streamline drug development.

Building on this core platform, DINA, Mavatar is also developing a blood test-based clinical decision support tool, currently focused on oncology. The goal is to ensure patients receive the right treatment at every step—improving survival rates and reducing the need for costly and ineffective “trial & error” approaches.

The platform is the result of more than 20 years of research into how compounds interact with individual biology at a molecular level, with a focus on intracellular and cell-to-cell communication, as well as transcriptomics. Using digital twin technology, Mavatar creates advanced disease models tailored to individual patients.

Founded in 2018, Mavatar is led by CEO Johan Juhlin, who brings extensive experience from multiple medtech companies. The company employs around 30 people, including 25 PhDs.

In 2024, Mavatar raised SEK 40 million at a valuation of SEK 300 million. The round was primarily backed by existing investors, including the Oldmark family, Wictor Family Office, Maria Rankka, and Johan Staël von Holstein.

Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered [insert location], Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.

The Company has partnerships with leading pharmaceutical companies, universities, and hospital systems. These collaborations focus on biobank studies and clinical trials, enabling research scientists to select the best drug candidates, suggest new uses for existing drugs, uncover new therapeutic targets, refine mechanisms of action, and match patients to innovative treatment options through point-of-care decision tools.

Connect with us on LinkedIn.